(1S,2R)-1-((2R,3R,4S)-4-acetoxy-3-(2-azidoacetamido)-6-(methoxycarbonyl)-3,4-dihydro-2H-pyran-2-yl)propane-1,2,3-triyl triacetate | 1261081-32-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1S,2R)-1-((2R,3R,4S)-4-acetoxy-3-(2-azidoacetamido)-6-(methoxycarbonyl)-3,4-dihydro-2H-pyran-2-yl)propane-1,2,3-triyl triacetate
• 英文别名: 5-(N-2-azido)acetyl-4,7,8,9-tetra-O-acetyl-2,3,5-trideoxy-D-glycero-D-galacto-2-nonulopyranosonate
• CAS: 1261081-32-6
• 化学式: C₂₀H₂₆N₄O₁₂
• 分子量: 514.446
• InChiKey: JLWGJFGKSPRYGX-RSACRBQFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  36.0
• 可旋转键数：
  11.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  218.59
• 氢给体数：
  1.0
• 氢受体数：
  13.0

反应信息

• 作为反应物：
  描述：

  (1S,2R)-1-((2R,3R,4S)-4-acetoxy-3-(2-azidoacetamido)-6-(methoxycarbonyl)-3,4-dihydro-2H-pyran-2-yl)propane-1,2,3-triyl triacetate 在 甲醇 、 sodium methylate 、 copper(II) sulfate 、 sodium ascorbate 作用下， 以 二氯甲烷 、 水 、 正丁醇 为溶剂， 反应 1.0h， 生成 (2R,3R,4S)-3-(2-(4-ethoxy-1H-1,2,3-triazol-1-yl)acetamido)-4-hydroxy-2-((1R,2R)-1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-carboxylate
  参考文献：
  名称：

  Inhibition of human neuraminidase 3 (NEU3) by C9-triazole derivatives of 2,3-didehydro-N-acetyl-neuraminic acid

  摘要：

  We report the synthesis of a series of C9 and N5Ac modified analogs of 2,3-didehydro-N-acetyl-neuraminic acid (DANA) and their inhibitory potency for the human neuraminidase 3 (NEU3) enzyme. We were able to generate a small library of compounds through the synthesis of azide derivatives of DANA, followed by Cu-catalyzed azide-alkyne cycloaddition (CuAAC) to generate triazole-containing inhibitors. Our results suggest that NEU3 can tolerate large hydrophobic groups at the C9 position; however, none of the derivatives made at the N5Ac side-chain were active. We identify three new inhibitors that have comparable potency to the best reported inhibitors of the enzyme. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.111
• 作为产物：
  描述：

  2,3-dehydroneuraminic acid 在 吡啶 、 4-二甲氨基吡啶 、 sodium methylate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 18.5h， 生成 (1S,2R)-1-((2R,3R,4S)-4-acetoxy-3-(2-azidoacetamido)-6-(methoxycarbonyl)-3,4-dihydro-2H-pyran-2-yl)propane-1,2,3-triyl triacetate
  参考文献：
  名称：

  Inhibition of human neuraminidase 3 (NEU3) by C9-triazole derivatives of 2,3-didehydro-N-acetyl-neuraminic acid

  摘要：

  We report the synthesis of a series of C9 and N5Ac modified analogs of 2,3-didehydro-N-acetyl-neuraminic acid (DANA) and their inhibitory potency for the human neuraminidase 3 (NEU3) enzyme. We were able to generate a small library of compounds through the synthesis of azide derivatives of DANA, followed by Cu-catalyzed azide-alkyne cycloaddition (CuAAC) to generate triazole-containing inhibitors. Our results suggest that NEU3 can tolerate large hydrophobic groups at the C9 position; however, none of the derivatives made at the N5Ac side-chain were active. We identify three new inhibitors that have comparable potency to the best reported inhibitors of the enzyme. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.111

文献信息

• [EN] METHODS OF MODULATING LEUKOCYTES ACTIVATION AND THROMBOCYTE CLEARANCE WITH INHIBITORS OF SPECIFIC NEURAMINIDASE ISOENZYMES<br/>[FR] MÉTHODES DE MODULATION DE L'ACTIVATION DES LEUCOCYTES ET DE LA CLAIRANCE DES THROMBOCYTES AVEC DES INHIBITEURS D'ISOENZYMES DE NEURAMINIDASE SPÉCIFIQUES
  申请人：PCHEJETSKI ALEXEY

  公开号：WO2020107124A1

  公开（公告）日：2020-06-04

  The present invention provides a method of modulating leukocytes activation (e.g., adhesion and/or transmigration and/or cytokine response) and a method of modulating thrombocyte clearance comprising administering to a subject in need thereof a specific inhibitor of neuraminidase 1 (neu1); neuraminidase 3 (neu3) or neuraminidase 4 (neu4); or a bispecific inhibitor of neu1, neu3 or neu4 of formula (I): (I) Also provided are pharmaceutical compositions comprising the inhibitor compound of formula (1), and uses thereof for modulating leukocytes activation or modulating thrombocyte clearance.

  本发明提供了一种调节白细胞活化（例如，粘附和/或跨膜迁移和/或细胞因子反应）的方法，以及一种调节血小板清除的方法，包括向需要的受试者施用神经氨酸酶1（neu1）的特异性抑制剂；神经氨酸酶3（neu3）或神经氨酸酶4（neu4）；或式（I）的神经氨酸酶1、神经氨酸酶3或神经氨酸酶4的双特异性抑制剂：（I）。还提供了包括式（1）的抑制剂化合物的药物组合物，以及用于调节白细胞活化或调节血小板清除的用途。
• Selective Inhibitors of Human Neuraminidase 1 (NEU1)
  作者：Tianlin Guo、Rachel Héon-Roberts、Chunxia Zou、Ruixiang Zheng、Alexey V. Pshezhetsky、Christopher W. Cairo

  DOI：10.1021/acs.jmedchem.8b01411

  日期：2018.12.27

  Inhibitors of human neuraminidase enzymes (NEU) are recognized as important tools for the study of the biological functions of NEU and will be potent tools for elucidating the role of these enzymes in regulating the repertoire of cellular glycans. Here we report the discovery of selective inhibitors of the human neuraminidase 1 (NEU1) and neuraminidase 2 (NEU2) enzymes with exceptional potency. A library

  人神经氨酸酶（NEU）的抑制剂被认为是研究NEU生物学功能的重要工具，将是阐明这些酶在调节细胞聚糖组成中的作用的有效工具。在这里，我们报告发现人类神经氨酸酶1（NEU1）和神经氨酸酶2（NEU2）酶具有特殊效力的选择性抑制剂的发现。修饰的2-deoxy-2,3-didehydro- N的文库合成了具有乙酰基神经氨酸（DANA）类似物的C5-或C9位置，并针对四种人类神经氨酸酶同工酶（NEU1-4）进行了评估。NEU1可以很好地容纳在C5和C9位置带有酰胺连接基的疏水基团，并且发现一个六氨基基团在两个位置均具有最佳效价。尽管C5-六氨基-C9-六氨基-DANA类似物未显示出协同修饰的协同改进，但在单个位置上延伸的烷基酰胺与第二个位置上的较小基团相结合，增强了效力。确定的最佳NEU1抑制剂是具有K i与其他同工酶相比，具有53±5 nM的选择性和340倍的选择性。此外，我们证明了C5修饰结合C